MARC HOROWITZ to Adult
This is a "connection" page, showing publications MARC HOROWITZ has written about Adult.
Connection Strength
0.088
-
Stressors and strains of medical training and practice. Swiss Med Wkly. 2003 Dec 13; 133(45-46):629.
Score: 0.013
-
Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer. 1996 Aug 15; 78(4):901-11.
Score: 0.008
-
Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy. J Clin Oncol. 1996 Mar; 14(3):901-10.
Score: 0.008
-
Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996 Feb; 14(2):362-72.
Score: 0.008
-
Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol. 1993 Oct; 11(10):1911-8.
Score: 0.007
-
Pulmonary metastases: MR imaging with surgical correlation--a prospective study. Radiology. 1992 Jan; 182(1):123-9.
Score: 0.006
-
Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. Int J Radiat Oncol Biol Phys. 1991 Mar; 20(3):389-95.
Score: 0.006
-
A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. J Neurooncol. 2006 Apr; 77(2):193-8.
Score: 0.004
-
Therapy for childhood soft-tissue sarcomas other than rhabdomyosarcoma: a review of 62 cases treated at a single institution. J Clin Oncol. 1986 Apr; 4(4):559-64.
Score: 0.004
-
Reoperative pulmonary metastasectomy for sarcomatous pediatric histologies. Ann Thorac Surg. 1998 Sep; 66(3):908-12; discussion 913.
Score: 0.002
-
Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol. 1996 Oct; 14(10):2818-25.
Score: 0.002
-
Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996 Aug 01; 78(3):527-31.
Score: 0.002
-
Metastasectomy for sarcomatous pediatric histologies: results and prognostic factors. Ann Thorac Surg. 1995 Jun; 59(6):1385-9; discussion 1390.
Score: 0.002
-
Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med. 1995 Jan 19; 332(3):143-9.
Score: 0.002
-
Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 1994 Oct 01; 84(7):2221-8.
Score: 0.002
-
Sarcomas of the hand and foot: analysis of local control and functional result with combined modality therapy in extremity preservation. Int J Radiat Oncol Biol Phys. 1994 Jul 01; 29(4):735-45.
Score: 0.002
-
A phase II evaluation of thiotepa in pediatric central nervous system malignancies. Cancer. 1993 Jul 01; 72(1):271-5.
Score: 0.002
-
Cytogenetic studies in subgroups of rhabdomyosarcoma. Genes Chromosomes Cancer. 1992 Nov; 5(4):299-310.
Score: 0.002
-
Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res. 1991 Sep; (270):8-14.
Score: 0.001
-
Phase II trial of sequential methotrexate and 5-fluorouracil with leucovorin in children with sarcomas. Invest New Drugs. 1990 May; 8(2):181-2.
Score: 0.001
-
Intensive combined modality therapy of small round cell and undifferentiated sarcomas in children and young adults: local control and patterns of failure. Radiother Oncol. 1989 Nov; 16(3):189-201.
Score: 0.001
-
Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy. Cancer Res. 1987 Mar 01; 47(5):1457-60.
Score: 0.001
-
Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna. Cancer Treat Rep. 1987 Feb; 71(2):127-30.
Score: 0.001
-
Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep. 1987 Feb; 71(2):131-5.
Score: 0.001
-
Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity. Cancer Chemother Pharmacol. 1987; 19(1):57-60.
Score: 0.001
-
Enhancement of methotrexate nephrotoxicity after cisplatin therapy. Cancer. 1986 Dec 15; 58(12):2617-21.
Score: 0.001